2019 Conference Speakers
Clint Lewis is executive vice president and group president responsible for International Operations, Commercial Development and Lifecycle Innovation, Global Genetics, Aquatic Health and Human Medical Diagnostics at Zoetis. In this role, he is responsible for all markets outside the United States. Mr. Lewis also oversees the company’s global commercial development and new product strategy, as well as the Global Genetics business and PHARMAQ, the company’s aquaculture business.
Mr. Lewis previously served as president, International Operations at Zoetis (2015-2018) and president, U.S. Operations at Zoetis (2013-2015). Prior to the formation of Zoetis, he served as president, U.S. Operations, for Pfizer Animal Health, which he joined in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in the human health pharmaceutical segment and held positions of increasing responsibility across various commercial and general management roles dedicated to human health.
In addition to his responsibilities at Zoetis, Mr. Lewis served as the former vice chair and chairman for the Animal Health Institute (AHI), the trade association for the animal health industry in the U.S. (2009-2012). He also served as the treasurer for Animal Health Europe, the trade association for the animal health industry in Europe (2016-2018).
Mr. Lewis serves as a member of the Board of Directors for International Paper, where he is a member of the Governance and Public Policy, Environment and Sustainability subcommittees.
Mr. Lewis has been recognized by Black Enterprise Magazine as one of its 300 Most Powerful Executives, and by Savoy magazine as one of its Top 100 most influential African-Americans in Corporate America.
Charles Hoare has almost 20 years of experience in healthcare investment banking. Prior to joining Stifel, he was Managing Director and Head of Global Healthcare at Commerzbank. He spent most of his career at Merrill Lynch, where he was the Managing Director responsible for the Northern European healthcare business and the animal health franchise.
He serves as Chairman of the Bulldog Trust, Chairman of Chariot Innovations Limited (the commercialisation arm of the London School of Hygiene and Tropical Medicine), and is a Non-executive Director of Placehill Limited, and Laguna Ventures Limited.
Ivo Claassen started his career over thirty years ago at the National Institute for Public Health and Environment in the Netherlands. From there, he moved to the Dutch Veterinary Research Institute in Lelystad where he has occupied various positions. Dr Claassen has been involved in R&D, production, QA/QC and regulatory aspects of human and veterinary medicines. He has developed and executed projects in Asia, Africa and the Middle-East on capacity building of institutional infrastructure for veterinary infectious disease control. He was a co-opted member of the Committee for Medicinal Products for Veterinary Use (CVMP) for the quality of veterinary biotechnological medicines. Since 2018 he has held the position at the European Medicines Agency as Head of the Veterinary Medicines Division.
Zach Bush, MD is a triple board-certified physician with expertise in internal medicine, endocrinology and metabolism, and hospice and palliative care. His basic science and clinical research over the last 17 years have moved from chemotherapy development to the role of the microbiome in human health. As founder and CEO of Seraphic Group, Inc. Zach has started over a dozen companies in pursuit of root cause solutions in the areas of health, energy, and ecology. Through his teams’ investigation in these areas, he has discovered that disruption of natural carbon cycles is common in all sectors. With this unifying science, he has launched a global education campaign with the Farmer’s Footprint docuseries and non-profit, that brings consumer and corporate support to farmers prepared to transition from chemical farming to regenerative agriculture and create a healthier future.
With more than 25 years of experience building and transforming sales teams into effective and targeted revenue drivers, Rob is uniquely positioned to deliver sales structure and process alignment driving predictable growth.